Common variants in the regulative regions of GRIA1 and GRIA3 receptor genes are associated with migraine susceptibility by Formicola, Daniela et al.
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Formicola, Daniela, Aloia, Andrea, Sampaolo, Simone, Farina, Olimpia,
Diodato, Daria, Griffiths, Lyn R., Gianfrancesco, Fernando, Di Iorio,
Giuseppe, & Esposito, Teresa (2010) Common variants in the regulative
regions of GRIA1 and GRIA3 receptor genes are associated with migraine
susceptibility. BMC Medical Genetics, 11(1), p. 103.
This file was downloaded from: http://eprints.qut.edu.au/62590/
c© Copyright 2010 BioMed Central Ltd.
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
http://dx.doi.org/10.1186/1471-2350-11-103
This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted
PDF and full text (HTML) versions will be made available soon.
Common variants in the regulative regions of GRIA1 and GRIA3 receptor genes
are associated with migraine susceptibility
BMC Medical Genetics 2010, 11:103 doi:10.1186/1471-2350-11-103
Daniela Formicola (formicola@igb.cnr.it)
Andrea Aloia (aloia.andrea@libero.it)
Simone Sampaolo (simone.sampaolo@unina2.it)
Olimpia Farina (ofarina@hotmail.it)
Daria Diodato (daria.diodato@unina2.it)
Lyn R Griffiths (l.griffiths@griffith.edu.au)
Fernando Gianfrancesco (gianfrancesco@igb.cnr.it)
Giuseppe Di Iorio (giuseppe.diiorio@unina2.it)
Teresa Esposito (teresa.esposito@igb.cnr.it)
ISSN 1471-2350
Article type Research article
Submission date 21 January 2010
Acceptance date 25 June 2010
Publication date 25 June 2010
Article URL http://www.biomedcentral.com/1471-2350/11/103
Like all articles in BMC journals, this peer-reviewed article was published immediately upon
acceptance. It can be downloaded, printed and distributed freely for any purposes (see copyright
notice below).
Articles in BMC journals are listed in PubMed and archived at PubMed Central.
For information about publishing your research in BMC journals or any BioMed Central journal, go to
http://www.biomedcentral.com/info/authors/
BMC Medical Genetics
© 2010 Formicola et al. , licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  1
Common variants in the regulative regions of GRIA1 and GRIA3 
receptor genes are associated with migraine susceptibility 
 
Daniela Formicola1, Andrea Aloia1, Simone Sampaolo2, Olimpia Farina2, Daria 
Diodato2, Lyn R. Griffiths3, Fernando Gianfrancesco1, Giuseppe Di Iorio2 and Teresa 
Esposito1,§. 
 
1Institute of Genetics and Biophysics, Italian National Research Council, Naples, 
Italy. 
2Headache Service - Department of Neurological Sciences, Second University of 
Naples, Naples, Italy. 
3Genomics Research Centre, School of Medical Science, Griffith University, Gold 
Coast, Queensland, Australia. 
 
 
 
§ Corresponding Author: Teresa Esposito 
    Human Genetics Disease Laboratory 
    Institute of Genetics and Biophysics, CNR 
    Via P. Castellino 111 – 80131 Naples, Italy 
    Phone: +39-081 6132330 
    Fax No: +39-081 6132617 
    Email address: teresa.esposito@igb.cnr.it 
  2
Abstract: 
Background: 
Glutamate is the principal excitatory neurotransmitter in the central nervous system 
which acts by the activation of either ionotropic (AMPA, NMDA and kainate 
receptors) or G-protein coupled metabotropic receptors. Glutamate is widely accepted 
to play a major role in the path physiology of migraine as implicated by data from 
animal and human studies. Genes involved in synthesis, metabolism and regulation of 
both glutamate and its receptors could be, therefore, considered as potential 
candidates for causing/predisposing to migraine when mutated.  
Methods: 
The association of polymorphic variants of GRIA1–GRIA4 genes which encode for 
the four subunits (GluR1–GluR4) of the alpha-amino-3- hydroxy-5-methyl-4-
isoxazole-propionic acid (AMPA) receptor for glutamate was tested in migraineurs 
with and without aura (MA and MO) and healthy controls.  
Results: 
Two variants in the regulative regions of GRIA1 (rs2195450) and GRIA3 (rs3761555) 
genes resulted strongly associated with MA (P=0.00002 and P=0.0001, respectively), 
after correction for multiple comparisons, but not associated with MO, suggesting 
their role in cortical spreading depression. Whereas the rs548294 variant in GRIA1 
gene showed association primarily with MO phenotype, supporting the hypothesis 
that MA and MO phenotypes could be genetically related. These variants modify 
binding sites for transcription factors altering the expression of GRIA1 and GRIA3 
genes in different conditions.  
Conclusions: 
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This study represents the first genetic evidence of a link between glutamate receptors 
and migraine. 
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Background: 
Migraine is a multifactorial disorder in which genetic factors play a relevant role in 
both predisposing and determining underlying mechanisms. Approaches to identified 
genes for monogenic subtypes migraine (e.g. Familial Hemiplegic Migraine – FHM) 
has been successful (CACNA1A, ATP1A2, SCN1A genes causing FMH 1, 2 and 3 
respectively) [1-4]. Conversely, finding genes for the most frequent types of migraine 
(with and without aura) and defining their pathogenic role has proven much more 
difficult [5]. However, synaptic hyper-excitability has been invocated as one major 
pathogenic mechanism in both common and monogenic forms of migraine, and data 
from animal (experimental cortical spreading depression; c-fos protein expression at 
the trigeminal nucleus caudalis, plasma protein extravasations at level of dura-mater 
circulation, electrophysiological studies) [6,7] and human (assessment of glutamate 
concentration in plasma, platelets and cerebrospinal fluid in migraneurs vs. control, 
glutamate and migraine symptoms; glutamate and sensitization) [8] studies suggest 
that glutamate is one of the principal factors involved.  
Glutamate is the major excitatory neurotransmitter in the central nervous system 
which exerts this action mainly through its interaction with its ionotropic or 
metabotropic receptors.  
In this study we investigated the association of GRIA1, GRIA2, GRIA3 and GRIA4 
genes that encode for the four subunits (GluR1–GluR4) of the alpha-amino-3-
hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) ionotropic receptor and their 
variants to migraine with and without aura (MA and MO). 
This is the first study that shows a significant association between genetic variants of 
glutamate receptor and MA.  
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Methods: 
Population Collection & Phenotype: 
Two hundred fifty outpatients consecutively observed from January 2006 to 
December 2008 at the Service of Diagnosis and Therapy of Headache of the Second 
University, Naples and two hundred sixty healthy volunteers consecutively enrolled 
during the same time interval were included in the study. Cases and controls were 
matched for sex, came from the same small geographical area and were Caucasian. 
All gave informed consent to the research procedures including molecular genetic 
analyses. The study protocol included history, direct clinical and neurological 
examination, MRI with both arterial and venous angiography sequences; venous 
blood collection for routine blood analysis as well as DNA extraction from 
lymphocytes according to standard salting out procedure [9]. Migraineurs were 
diagnosed as having either migraine with (MA) or migraine without (MO) aura, 
according to the 2004 International Headache Society [10] diagnostic criteria.  The 
study population was comprised of 244 migraineurs (M/F 56/188; age 14-64 years; 
MA/MO 135/109); 7 patients who resulted affected with Familial Hemiplegic 
Migraine were excluded from the study.   
For the statistical analysis three experimental groups were considered: all migraineurs 
together (MA+MO= M) and MA and MO separately. Healthy control individuals (204 
females and 56 males aged 21–64 years) of Caucasian origin  matching for age and 
sex the migraineurs served as control for all three experimental groups. 
 
Polymorphisms selection and Genotyping: 
SNP selection was performed inspecting the HapMap database PhaseIII/Rel 2, Feb09 
on NCBI B36 assembly, dbSNP b126 (http://www.hapmap.org/index.html.en). 
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Default parameters in Haploview were used to create haplotype blocks (95% 
confidence intervals) as described by   Gabriel et al (2002) [11]. 
TagSNPs were selected at an r2 threshold of 0.80 from all SNPs with minor allele 
frequency (MAF) >0.15 allowing us to capture more than 80% of the haplotypic 
diversity of these genes. 
GRIA1. The gene maps on chromosome 5q33.2 and spans a genomic region of about 
320 kb. After consulting the HapMap database 
(http://www.hapmap.org/index.html.en), we identified along the 320 kb of the GRIA1 
gene four main blocks of linkage disequilibrium (LD) with few major haplotypes. The 
first block included the first two GRIA1 exons and the 5’ upstream region. The second 
block was in intron 2, the third block included the exons 3-5, and the remaining part 
of the GRIA1 gene and the end was in the fourth block of LD. In consideration of the 
extension of LD inside each block we selected two SNPs in the first block, two SNPs 
in the fourth block and one SNP in the second and third blocks. In particular, the 
SNPs chosen were: rs548294, rs2195450, rs1463747, rs2963954, rs4530817 and 
rs1461225 (figure 1). All SNPs were genotyped by restriction digestion using the 
enzymes MwoI, TaqI, BsgI, RsaI, MnlI, and HpaI respectively. 
GRIA2. For the GRIA2 gene, that expands a genomic region of 143 kb on 
chromosome 4q32.1, two main blocks of LD were identified. We selected four SNPs 
(two for each block): rs13138842, rs11946396, rs28495775 and rs11728471 that were 
genotyped by restriction digestion using the enzymes MluI, AccII, HuncII, and HphI 
respectively (figure 1). 
GRIA3. The GRIA3 gene spans a genomic region of about 300 kb consisting of 17 
exons, and is located in Xq24-q28 region, a critical region for migraine [12]. In a 
previous unpublished study we completely sequenced the coding and regulative 
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regions of the GRIA3 gene in ten Italian migraine patients. We detected only a 
synonymous sequence variation in coding region C/T N400N (rs502434), and a 
number of SNPs located in intronic and promoter region. Taking in account SNPs 
distribution and LD-plot for GRIA3 gene, in a first step we selected 8 SNPs located in 
different LD-blocks: -1952T/C SNP (rs3761555) in the promoter region, the G/A 
SNP rs12559450 in intron 2, the G/A SNP rs4825840 in intron 2, the C/A SNP 
rs4825849 in intron 3, the T/C SNP rs5911598 in intron 5, the C/T SNP N400N 
(rs502434) in exon 9, the C/T SNP rs2354037 in intron 12 and the T/C SNP 
rs5910006 in intron 14 (figure 1). In a preliminary analysis, using a smaller size 
cohort of migraine patients and controls (100 cases vs 100 controls) only one SNPs 
rs3761555 showed a trend of allelic differences between cases and controls, than was 
analysed in more detail. Genotyping was performed by restriction digestion using the 
enzyme BglII. 
GRIA4. Also for the GRIA4 gene, which spans over 370 kb on chromosome 11q22.3, 
only two main blocks of LD were identified. We selected four SNPs (two for each 
block): rs11226805, rs590928, rs649098 and rs589104 that were genotyped by 
restriction digestion using the enzymes DdeI, Eco57I, MboI, and NlaIII respectively 
(figure 1). 
All PCRs were performed as described in our previous work [13]. 
Briefly, PCR reactions (10µl final volume) containing 2 mmol/L MgCl2, 0.5 mol/L of 
each primer, 200 mol/L dNTPs, 1 unit of Taq polymerase (Fermentas) and 
approximately 20 ng of genomic DNA were undertaken for genotyping purposes. 
Thermal cycling was performed with an initial denaturation of 180 seconds at 94°C, 
followed by 35 cycles of 30 sec at 94°C, 30 sec at melting temperature (MT), 30 sec 
at 72°C, and a terminal extension of 10 min at 72°C. PCR products were then 
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digested with restriction enzymes and analyzed by electrophoresis on 3% agarose 
gels. Ethidium bromide stained gels were digitally imaged and manually scored for 
genotypes. Table 1 shows the oligo sets and genotyping procedures for the GRIA1 and 
GRIA3 associated SNPs. 
 
Association Analysis: 
To detect association between the tested markers and migraine, we performed chi-
square (χ²) analysis to test for significant differences in allele and genotype 
frequencies in case versus control results. χ² provides the likelihood of a deviation in 
the distribution of the same attributes in different classes (e.g. allelic frequencies in 
controls versus affected subjects). If the probability (p-value) of an equal distribution 
between the two groups is below a determined significance level α (in percent), the 
statistical output will show enough significance to assume LD and therefore 
association. The p value of this test is asymptotically equal to the p value obtained in 
Armitage’s trend test (ATT). ATT takes into account genotypes rather than alleles, 
avoiding a possible bias caused by doubling the sample size. It assumes an additive 
(or co-dominant) disease model where all disease alleles have equal and independent 
contribution to disease risk. The ATT is valid and powerful under a broad range of 
disease mechanisms. Second, allele and genotype frequencies, dominant and recessive 
genetic models as well as odds ratios were calculated to characterise the distribution 
of a distinct genotypes in different phenotypic subgroups of the population (using 
FINETTI, http://ihg.ghs.de/cgi-bin/hw/hwa1.pl). Hardy-Weinberg Equilibrium 
(HWE) was also calculated using FINETTI. The analysis of the statistical power was 
performed using the Genetic Power Calculator software 
(http://pngu.mgh.harvard.edu/~purcell/gpc/cc2.html) [14] assuming a significance 
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level (α) of 0.05, a lifetime risk of 2, and the MAF of each SNP as calculated in our 
control group. In the population-based association analysis, the nominal significance 
threshold was set at P < 0.05 and lowered to P < 0.0017 after the multiple comparison 
correction of Bonferroni considering 22 SNPs, the three clinical groups analyzed, 
genotypes-alleles and females-males. Confidence intervals at 95% are provided for all 
odds-ratio (OR) values. Haplotype frequencies were calculated using the Estimation 
Haplotype (EH) program (Jurg Ott, Rockefeller University). A P level of less than 
0.05 was considered statistically significant. 
 
Electrophoretic mobility shift assays: 
To determine whether the c.-1952T>C SNP in GRIA3 promoter region alters nuclear 
protein-DNA interactions, EMSAs was performed using radio-labelled 
oligonucleotide probes containing either -1952T or -1952C. Nuclear extracts were 
prepared from HEK 293 and SH5Y5Y cell lines as described by Granelli-Piperno et 
al. [15]. Binding reactions mixture contained 10 ng 32P-labeled oligonucleotide probe 
(105 cpm), 15 µg nuclear extract, 2 µg poly (dI-dC), 100 mM KCl, 10mM MgCl2, 
20mM HEPES (pH 7.9), 0.2 mM EDTA, 0.5 mM dithiothreitol, 20% glycerol and 
protease inhibitor, in a total vol of 20 µl. To perform super shift experiments, 2 µg of 
the anti-HSF1 antibody (Celbio) was added to the binding reaction mixture. In 
competition experiments, 100-fold molar excess of cold oligonucleotides was added 
to the binding reaction mixture. Reaction mixtures were incubated for 30 min at room 
temperature, resolved on non-denaturing 5% polyacrylamide gel, dried, and exposed 
to autoradiography. The same assay was performed for the c.-2012C>T SNP 
rs548294 in GRIA1 promoter region and for c.+561G>A SNP rs2195450 in intron 1.  
Primers used for GRIA3 SNP were: 
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GRIA3-T-EMSA-F ATGGAGACAAAAGATTTCTATGAGTGGTGGGTGGG 
GRIA3-T-EMSA-R TCCTCCCACCCACCACTCATAGAAATCTTTTGTCT 
GRIA3-C-EMSA-F ATGGAGACAAAAGATCTCTATGAGTCGTGGGTGGG 
GRIA3-C-EMSA-R TCCTCCCACCCACGACTCATAGAGATCTTTTGTCT 
Primers used for GRIA1 SNP rs548294 were: 
GRIA1PROMF-T CAGTGCTTGCTGTTATTAGAGCCT 
GRIA1PROMR-T TCTTAGGCTCTAATAACAGCAAGC 
GRIA1PROMF-C CAGTGCTTGCTGCTATTAGAGCCT 
GRIA1PROMR-C TCTTAGGCTCTAATAGCAGCAAGC 
Primers used for GRIA1 SNP rs2195450 were: 
GRIA1intF-G  AAAGAGACCCTCGAGAAGAAGGAG 
GRIA1intR-G  CTCACTCCTTCTTCTCGAGGGTCT 
GRIA1intF-A  AAAGAGACCCTCAAGAAGAAGGAG 
GRIA1intR-A  CTCACTCCTTCTTCTTGAGGGTCT 
 
Luciferase assays: 
To test the functional activity of the T>C polymorphism in the promoter region of the 
GRIA3 gene, we first identified the putative start site at -823 to the ATG, using the 
Promoter scan software vs2. A fragment of 1854 bp of the GRIA3 promoter 
encompassing base pairs -1411 to +325 (referred to the predicted start site) and 
including the T>C polymorphism was amplified from genomic DNA of migraine 
patients with genotype CC and controls with genotype TT. The primers used for 
generating this fragment were sense: 5'- 
GCGCGCCTCGAGTTTGAAGATGAGAGAACTGG-3' and antisense: 5'-
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GCGCGCAAGCTTCAAAAGAAAGAGAACGAAAG-3' which contain 5'-XhoI 
and 3'-HindIII restriction sites (highlighted bold sequences), respectively.  
PCR products were double digested using XhoI and HindIII and then legated into a 
linearized pGL3-Basic vector (Promega, Madison USA) containing a Firefly 
Luciferase reporter gene. The inserts of the constructs were verified by sequencing 
before transient transfection.  
Transfections were carried out using HEK293T cells. Cells were co-transfected with 1 
µg of reporter plasmid and 10 ng of pRL-TK control vector (Promega, Madison USA) 
containing Renilla luciferase, which was used to correct for transfection efficiency. 
Transfection cells were harvested after 24 h and cell lysates were assayed sequentially 
for Firefly and Renilla luciferase activity using a dual-reporter assay system 
(Promega, Madison USA). Transfections were performed in quadruplicate for each 
plasmid construct. Changes in gene transcription were calculated relative to the 
corrected luciferase activity of the empty pGL3-Basic vector (control).  
 
Ethical approval: 
This research was reviewed and approved by the University of Naples Human 
Research Ethics Committee and all subjects participating in the study gave informed 
consent. 
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Results: 
GRIA1 and GRIA3 genes are associated with migraine: 
We selected SNPs for each gene (GRIA1-GRIA4) considering their distribution in LD 
blocks (figure 1). All variants were genotyped in a well-characterized panel of 244 
cases and 260 controls (see methods). In controls, all SNPs analyzed are in Hardy–
Weinberg equilibrium (HWE) (with the exception of rs2195450) and showed allele 
frequencies comparable to those observed in the Caucasian population and reported in 
the HapMap or SNP browser databases.  
No significant association with the disease for any of the four SNPs in GRIA2 and 
GRIA4 genes tested was observed. 
Significant association was observed for two SNPs located in the first block of LD of 
GRIA1 gene including the regulative region and the first two exons. Allelic and 
genotype frequencies distribution of the promoter -2012C/T (rs548294) marker in 
cases and controls showed significant association with migraine (p=0.00009 and 
p=0.0005, respectively). Stratified analyses of migraine subtypes were also 
undertaken indicating association primarily attributed to MO subtype group 
(P=0.0003) and particularly in females (P=0.0007) (Table 2). These differences 
remained statistically significant when Bonferroni correction for multiple 
comparisons was applied (Migraine all: alleles p=0.002; genotypes p=0.01; MO 
alleles: p=0.008; genotypes p=0.03; Females all: alleles p=0.02; genotypes p=0.05) 
(Table 2). 
The analysis of the +561 G>A SNP (rs2195450) also showed significant association 
in both allelic and genotype distributions (p=0.0002 and p=0.0007, respectively) 
(p=0.005 and p=0.02 after Bonferroni corrections). Stratified analyses of migraine 
subtypes showed a specific association with MA subtype group for both allelic and 
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genotypic frequencies (p=0.00002 and p=0.00008) (p=0.0005 and p=0.002 after 
Bonferroni corrections) (Table 2). However, the SNP rs2195450, was the only SNP 
found in Hardy–Weinberg disequilibrium (DHW) both in controls and in patients 
(p<0.05). 
Regarding GRIA3 gene, we obtained statistically significant evidence for an 
association to migraine phenotype for the -1952T/C variant (rs3761555) located in the 
regulative region of the gene (allele C frequencies: controls-migraineurs = 22% vs. 
34%) (Table 2). In consideration of the X chromosomal localization of GRIA3 gene, 
we analyzed the data by gender, showing significant associations in females for both 
allelic and genotype distributions (p=0.0006 and p=0.0009, respectively). Stratified 
analyses of migraine subtypes showed a specific association with the female MA 
subtype group for either allelic or genotypic frequencies (p=0.0001 and p=0.0002, 
respectively) (Table 2). These differences remained statistically significant after 
Bonferroni correction (alleles p=0.003; genotypes p=0.005) (Table 2). The male 
group was not analyzed independently due to its limited size (n = 56). The statistical 
power for the three associated SNPs in GRIA1 and GRIA3 genes was 97% for 
rs548294, 97% for rs2195450 and 93% for rs3761555. When we calculated the 
statistical power for subgroups (MA, MO, females, males) it remained high in MA 
and females, but it decreased for MO and males subgroup due to their limited size. 
We analyzed the distribution of the haplotypes formed by the associated SNPs in 
GRIA1 gene in cases and controls. Haplotype frequencies (calculated using the EH 
program) were significantly different in cases and controls (chi-square = 12.72, df =3, 
p-value 0.005). Haplotype-specific testing showed that the putative risk haplotype 
T_A (rs548294- rs2195450) was more frequent in cases than in controls, resulting in 
p-value of 0.002 and an OR of 2.1. Conversely, the putative protective haplotype C_G 
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(rs548294- rs2195450) was more frequent in controls than in cases resulting in a p-
value of 0.00001 and an OR of 0.4 (Table 3).  
Possible additive interactions of the two most associated SNPs in GRIA1 (rs548294) 
and GRIA3 (rs3761555) genes were evaluated in those subjects who had both SNPs 
characterization. GRIA1 SNP rs2195450 was not analyzed because it was in HWD. In 
Migraine patients, the p-value for the sole risk allele of the GRIA1 gene (TT/TT, 
CT/TT genotypes) was 0.03, OR 1.68 (CI = 1.02-2.77); the p-value for the sole risk 
allele of the GRIA3 gene (CC/TC, CC/CC genotypes) was 0.005, 2.28 (CI = 1.27-
4.11) and the p-value for the combined two risk alleles (TT/TC, TT/CC, CT/TC, 
CT/CC genotypes) was 0.00001, OR 3.35 (CI = 1.96-5.74) (Table 4). 
 
-1952 T>C variant in GRIA3 regulative region have functional significance: 
Bioinformatics predictions by TRANSFAC [16] showed that the -1952T>C 
associated variant could affect the putative transcription factor binding sites HSF 
(Heat Shock Factor) and CdxA. To determine whether the c.-1952T>C SNP alters 
nuclear protein-DNA interactions, EMSAs were performed using radio-labelled 
oligonucleotide probes containing either -1952T or -1952C (see materials and 
methods). Two distinct complexes were revealed on incubation of the probes with 
nuclear extract from unstimulated HEK293T cells (figure 2A) and the -1952T probe 
showed stronger DNA protein-binding activity compared with the -1952C probe. 
EMSA assay was also performed using nuclear extract from neuroblastoma cell line 
SH5Y5Y and obtained the same results (data not shown). To further assess the 
binding specificity and the differences in binding affinity between the T and C allele, 
competition assay was performed with unlabeled -1952T or -1952C oligonucleotide. 
The results revealed that unlabeled -1952T oligonucleotide but not -1952C with 100- 
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fold molar excess fully blocked the binding of the radiolabeled -1952T probe or -
1952C probe with nuclear protein(s). Moreover, to determine if HSF1 is one of the 
transcription factors bound to the complexes, anti-HSF1 antibody was used in super 
shift assays. In these experimental conditions none of the complexes was specific for 
HSF1 (figure 2A). These data suggest that the -1952T>C polymorphism can affect the 
binding affinity of the GRIA3 promoter with several transcription factor(s) and the 
variant T allele has a stronger binding strength compared with the C allele. To test the 
functional effect of the -1952 T>C variant we performed the luciferase assay using the 
promoter region of GRIA3 gene. 
When HEK293T cells were transfected with the -1411 to +325 region, the luciferase 
activity generated by the C construct was similar to that generated by the T construct 
but interestingly, under heat shock condition (at 40°C for 1 h) the luciferase activity 
generated by the C construct was 1.3-fold greater than that generated by the T 
construct (figure 3).  
 
Functional analysis of the associated GRIA1 variants: 
Bioinformatics predictions did not show any clear alteration of transcription factor 
binding sites both for SNP -2012C>T and +561G>A. To determine whether these 
variations could alter nuclear protein-DNA interactions we performed EMSAs assays 
using radiolabelled oligonucleotide probes containing either -2012C or -2012T and 
+561G or +561A (see materials and methods) (figure 2B). No binding affinity was 
revealed for both +561G and +561A alleles. In contrast, two distinct complexes were 
revealed on incubation of the probes -2012T and -2012C with nuclear extract from 
unstimulated HEK293T cells and in particular, the -2012T probe showed stronger 
DNA protein-binding activity compared with the -2012C probe (figure 2B). The 
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binding specificity and the differences in binding affinity between the T and C allele 
was also demonstrated in competition assay using unlabeled -2012T or -2012C 
oligonucleotide. The results revealed that unlabeled -2012T oligonucleotide but not -
2012C with 100- fold molar excess fully blocked the binding of the radiolabeled -
2012T probe or -2012C probe with nuclear protein(s) (figure 2B). 
 
GRIAs comparative analysis: 
The identification of associated variants in the promoter regions of both GRIA1 and 
GRIA3 genes and their evidence for functional roles, suggested us to investigate about 
the evolutive conservation of this class of genes. We selected from databases the full-
length sequences of the transcripts of GRIA1-GRIA4 genes and the regulative regions 
at the 5’ of each gene. To postulate a coordinate regulation of these genes, all 
sequences were compared using the vista software and the results suggest that GRIA1 
seems be the ancestral gene and is more similar to GRIA3 gene as for other genes 
(GRIA2 and GRIA4) (figure 4). 
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Discussion: 
Glutamate is a major excitatory neurotransmitter in the central nervous system, 
thought to be widely involved in migraine mechanisms. Indeed, migraine brain 
nociceptive centres, including the trigeminal ganglion, trigeminal nucleus caudalis, 
and thalamus, contain glutamate-positive neurons, and glutamate activates the 
trigeminal nucleus caudalis. Glutamate is implicated in cortical spreading depression 
(CSD), trigemino-vascular activation, and central sensitization [17]. These 
observations argue for a strong link between migraine and the glutamatergic system. 
A link that is important to further characterization and understanding of migraine 
mechanisms in order to deliver effective therapies.  
In this study we have investigated the role of glutamate receptors, ionotropic, AMPA 
(GRIA1, GRIA2 GRIA3 and GRIA4 genes) and their variants in MA and MO. We 
found two variants in GRIA1 gene (rs548294 and rs2195450) and one variant in 
GRIA3 gene (rs3761555), all located in the regulative region of the genes, to be 
associated with the migraine phenotype in an Italian population. Interestingly, both 
the GRIA1 and GRIA3 variants were specifically associated with MA suggesting a 
role of these genes in CSD, which is retained to be the path physiological mechanism-
underlying aura. However, to date we cannot exclude that these variant can also be 
associated to MO phenotype due to limited size of MO subgroup. In fact, the 
rs548294 SNP in GRIA1 gene was primarily associated with MO rather than MA. 
Although MO and MA are separate categories according to the ICHD-II criteria these 
two subtypes of migraine share some path physiological mechanisms [18]. Several 
studies support that the same SNP or different SNPs in the same gene could be 
associated with both MO and MA phenotypes [5]. 
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We analyzed the distribution of the haplotypes formed by the associated SNPs in 
GRIA1 gene in cases and controls. Haplotype-specific testing showed that the putative 
risk haplotype T_A was more frequent in cases than in controls (13% and 7%, 
respectively, P = 0.001) and was associated with increased risk of migraine (OR = 
2,10; 95% CI (1.30- 3,12)) compared with the risk of the two alleles taken separately. 
Furthermore, our analysis of the combined effects of the two SNPs in GRIA1 
(rs548294) and GRIA3 (rs3761555) genes not supported a synergy of the two SNPs in 
the genetic susceptibility to migraine. Indeed, in migraine patients, the combined two 
risk allele genotypes exhibited an OR that was more or less the sum of the ORs of 
each risk allele taken separately, suggesting that, when both risk alleles are present, 
the risk to develop migraine is merely the sum of the effect carried by each single risk 
allele. 
Although our data need to be confirmed in more numerous series as well as in 
populations of different origin, the identification of a statistically significant genetic 
link between glutamate receptor genes and MA needs to be highlighted. A growing 
number of scientific report based on preclinical and clinical data argue strongly for a 
role of glutamatergic receptor activation in migraine and in particular in CSD [19]. 
Despite the remarkable advancing in the pharmacotherapy, there is still a tremendous 
need for the research of more effective treatments. Glutamate receptors antagonists 
have been recently proposed as major target addressed for the treatment of migraine. 
Glutamate receptors indeed represent a promising target for a valuable, non-
vasoactive oriented approach to the treatment of migraine [20]. 
The SNP rs2195450, which shows the strongest association, is in Hardy–Weinberg 
disequilibrium (DHW) both in controls and in patients. DHW may be due to several 
factors including genotyping errors, inappropriate population stratification and 
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selection, inbreeding, presence of a causative allele or simply the chance. We can 
exclude with high confidence that DHW as well as patient–control differences could 
be due to genotyping errors. For all SNPs, about 20 subjects were randomly selected 
and sequenced; for rs2195450 the sample was increased to 100 subjects. The original 
classification was confirmed in all samples. Moreover, for the autosome genes, the 
presence of DHW in different direction in controls and in patients, as observed for 
rs2195450, is compatible with the segregation of a causative variant according to a 
dominant model [21]. However, we cannot exclude that DHW is due to other 
confounding factors, and then the association of this SNP must be considered with 
prudence.  
Further remarkable in our cohort is that GRIA1 and GRIA3 variants are associated to 
migraine in female but not in male subjects.  To date we cannot assert that AMPA 
receptor genes and genetic variations within them may act differently in the two 
sexes, in light of the small sample size of case males that do not provide enough 
statistical power to detect association.  
However, the underlying mechanism by which these variants confer susceptibility to 
migraine remains unclear. Bioinformatics predictions showed that the C variant of 
GRIA3 gene could affect putative binding sites for transcription factors altering the 
consensus sequence. We strengthened this hypothesis by transfecting the HEK293T 
cells with a promoter region of GRIA3 gene. It should be highlighted that, under stress 
condition the luciferase activity generated by the C construct (associated allele) was 
1.3-fold greater than that generated by the T construct. Moreover, EMSA assays 
suggest that the -1952T>C polymorphism can affect the binding affinity of the GRIA3 
promoter with transcription factor(s) and the variant T allele has a stronger binding 
strength compared with the C allele. Considering that the T-allele displays lower 
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promoter transcription activity, we infer that the nuclear factor(s) bound to the region 
covering the -1952T>C polymorphism may function as negative regulator(s) for 
GRIA3 transcription. Therefore, the -1952T>C polymorphism may affect the GRIA3 
promoter binding affinity with nuclear proteins and in turn the GRIA3 expression, 
which consequently modulates the individual’s susceptibility to migraine. Future 
genetic and functional studies are necessary to further elucidate the role of GRIA3 in 
migraine susceptibility. Preliminary results using an Australian case-control panel 
indicate that the same -1952T>C polymorphism showed a trend of association with 
migraine (p=0.04) (L. Griffiths personal communication).  
More complex is the case of GRIA1 gene where only the -2012C>T variant seems to 
affect the binding affinity of the GRIA1 promoter with transcription factor(s) and the 
variant T allele has a stronger binding strength compared with the C allele. 
Considering that the T-allele is also the risk allele we can infer that nuclear factor/s 
bound to the region covering the -2012C>T polymorphism may function as positive 
regulator(s) for GRIA1 transcription. 
 
Conclusions:  
These results indicate an involvement of GRIA1 and GRIA3 genes in the susceptibility 
to migraine with aura and encourage replication in other data sets. Moreover, 
functional investigations to explain the role of glutamate receptors variants in MA 
might be useful.   
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Figure Legend: 
Figure 1: For each gene is reported the genomic structure, the LD plot with the 
genotyped SNPs.  
For GRIA3 gene the exons indicated in dark colour are alternative spliced in two 
different transcripts.  
Figure 2: A, electrophoretic mobility shift assay (EMSA) with radiolabeled either 
-1952T or -1952C probe and HEK-293 cell nuclear extracts (NE) and B, EMSA 
assays with radiolabeled either -2012T/-2012C and +561G/+561A probes and 
HEK-293 cell NE.  
A. Lanes 1 and 6, mobility of the labelled probes without NE; lanes 2 and 7, mobility 
of the labelled probes with NE in the absence of competitor. A specific nuclear 
protein binding can be almost completely abolished both by 100-fold unlabeled -
1952T but not with -1952C probe (lanes 4 and 5; lanes 9 and 10). Super shift assays 
incubating with anti-HSF1 antibody did not show any super shifted protein complex 
(lanes 3 and 8).  
B. Lanes 5, 10, 15 and 20, mobility of the labelled probes without NE; lanes 4, 9, 14, 
and 19, mobility of the labelled probes with NE in the absence of competitor. 
Competition assays with 100-fold unlabeled probes (lanes 1 and 2; lanes 6 and 7; 
lanes 11 and 12; lanes 16 and 17). Super shift assays incubating with anti-HSF1 
antibody did not show any super shifted protein complex (lanes 3, 8, 13 and 18). 
Figure 3: Luciferase assay for GRIA3 promoter activity.  
Under heat shock condition the luciferase activity generated by the C construct was 
1.3-fold greater than that generated by the T construct (p<0.05 using t-test 
calculation). 
Figure 4: Comparative analysis of GRIA1-GRIA4 genes.  
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A: comparison of GRIA1 coding region versus GRIA2, GRIA3 and GRIA4 cDNAs. B: 
phylogenetic tree. 
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